September 19, 2019

Theratechnologies Reaches Agreement with AIDS Drug Assistance Program (ADAP) for New Egrifta SVTM

Montreal, Canada – September 19, 2019 – Theratechnologies Inc. (TSX: TH) is pleased to announce that an agreement has been reached with the AIDS Drug Assistance Program Crisis Task Force for EGRIFTA SVTM (tesamorelin for injection), which will commercially launch in the United States very shortly. The agreement will help to facilitate access to low income, underinsured and uninsured Americans living with HIV in all 50 states and territories of the United States.

EGRIFTA SVTM is a growth hormone-releasing factor. On November 5, 2018, the FDA approved EGRIFTA SVTM for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.